Background: With the cytochrome P450 CYP2C19* 2 (* 2) allelic variant resulting in
complete loss of enzyme function and the CYP2C19* 17 (* 17) variant being linked to …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Background: A large number of clinical studies have documented that a loss‐of‐function
variant CYP2C19* 2 affects clinical profiles of clopidogrel (efficacy and safety). However …

Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented
gradually as the determinant conversion and variability in the antiplatelet effect of …

Background—The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in
clopidogrel metabolization. A recently explored CYP2C19* 17 allelic variant has been linked …

Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …

Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …

Clopidogrel, a prodrug, must be activated by hepatic cytochrome P450 (CYP) isoenzymes
before being able to irreversibly block the platelet adenosine 5′-diphosphate (ADP) …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …